How much funding has Innovent Biologics raised?

Innovent Biologics has raised $475.0M in total funding, most recently a Venture Round.

Who are Innovent Biologics's investors?

Innovent Biologics's investors include Legend Capital, Eli Lilly, Fidelity Management, Temasek, Hillhouse Capital, Fidelity Biosciences.

When was Innovent Biologics founded?

Innovent Biologics was founded in 2011.

Where is Innovent Biologics headquartered?

Innovent Biologics is headquartered in Suzhou, China.

What industry is Innovent Biologics in?

Innovent Biologics operates in Biotech, Healthcare.

How many employees does Innovent Biologics have?

Innovent Biologics has 5001-10000 employees.

Innovent Biologics

IPO

innovent

Public · Suzhou, China · Founded 2011 · $475.0M raised

Biotech

Healthcare

Headquarters: Suzhou
Employees: 5001–10000
Founded: 2011
Business Model: B2B
Website: en.innoventbio.com

Total Funding: $475.0M
Last Round: $80.0M Venture RoundJan 2025
Rounds: 5
Type: Public

About

Innovent Biologics (HKEX: 01801) is a leading biopharmaceutical company founded in 2011 and headquartered in Suzhou Industrial Park, Jiangsu, China. The company is dedicated to developing, manufacturing, and commercializing high-quality innovative medicines for oncology, metabolic diseases, autoimmune disorders, and other major conditions. Innovent has a vertically integrated R&D and manufacturing platform with over 140,000L of total production capacity and more than 5,600 employees. The company has strategic collaborations with Eli Lilly, Roche, Sanofi, and Incyte. Innovent went public on the Hong Kong Stock Exchange in 2018.

Summary

Innovent Biologics is a Biotech company based in Suzhou, China, founded in 2011. It has raised $475.0M in total across 5 rounds, most recently a $80.0M Venture Round round in Jan 2025. Investors include Legend Capital, Eli Lilly and Fidelity Management.

LinkedIn X (Twitter)